US 12,624,362 B2 · Mutant reverse tetracycline transactivators for expression of genes

Abstract

Provided herein are mutant reverse tetracycline transactivator (rtTA) proteins and engineered nucleic acids that encode a mutant rtTA that are useful in regulating gene expression, inducing cellular reprogramming, tissue repair, tissue regeneration, organ regeneration, reversing aging, treating a disease, or any combination thereof. Also provided herein are recombinant viruses comprising the engineered nucleic acids and methods of regulating cellular reprogramming, tissue repair, tissue regeneration, or any combination thereof by administering an engineered nucleic acid or recombinant virus comprising the same in a cell, tissue or subject comprising administering a mutant rtTA and an inducible nucleic acid encoding a transgene.

Claims27

Dependent claims

An engineered nucleic acid comprising a promoter operably linked to a first nucleic acid comprising a sequence that is at least 80% identical to the sequence of SEQ ID NO:

12, wherein the first nucleic acid sequence encodes a mutant reverse tetracycline transactivator (rtTA) comprising an amino acid sequence at least 70% identical to the sequence of SEQ ID NO:
11, which comprises the following mutations relative to rtTA3 (SEQ ID NO:
11):
(a) a G72V mutation;
(b) a G12S or G12T mutation;
(c) an F67S or F67T mutation;
and
(d) an R171K or R171H mutation.

5 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/280,294Filed 27 Sep 2019 · us provisional application

Priority

28 Sep 2018

Published

US 2021/0403923 A130 Dec 2021

Granted

12 May 2026

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C12N 15/63
Recombinant DNA-technology: introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N 15/635
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression: externally inducible repressor…
A61K 48/0058
Characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered: nucleic acids adapted for tissue…
C12N 15/86
For animal cells: viral vectors

Mutant reverse tetracycline transactivators for expression of genes

Life of this patent

Mutant reverse tetracycline transactivators for expression of genes

Life of this patent

Abstract

Claims27